PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of schbulschizophrenia bulletinsubscriptionscontact uscurrent issuemy basketarchivemy accountsearchcontact this journaloxford journalsabout this journal
 
Schizophr Bull. 2009 May; 35(3): 491–492.
Published online 2009 April 2. doi:  10.1093/schbul/sbp014
PMCID: PMC2669585

Chlorpromazine Dose for People With Schizophrenia

Background

Chlorpromazine is one of the 3 listed medicines for treating psychotic disorders in the World Health Organization's Essential Drug List. It is used across the globe for the 1% of people who suffer from this illness. Chlorpromazine has many adverse effects, including a range of movement disorders and anticholinergic and antihistaminic effects. Higher doses cause more adverse effects, but the evidence for which dose gives best clinical response for least adverse effects has not been carefully summarized for decades.

Objectives

To determine chlorpromazine dose-response and dose-adverse effect relationships for schizophrenia and schizophrenia-like psychoses.

Search Methods

We searched the Cochrane Schizophrenia Group Trials Register (December 2008). References of all included studies were examined for further trials.

Selection Criteria

All relevant randomized clinical trials (RCTs) were included as selection criteria.

Data Collection and Analysis

We extracted data independently. For dichotomous data, we calculated relative risk (RR) and their 95% confidence intervals (CIs). For continuous data, we calculated weighted mean differences based on a fixed-effect model.

Results

We included 4 relevant studies (1012 participants). They are all hospital-based trials and have a duration of less than 6 months. The trials compared chlorpromazine low dose (<400 mg/d) with medium dose (400–800 mg/d) and high dose (>800 mg/d). There were no convincing differences between low and medium doses for measures of mental state. These ratings were based on the results of one small trial (n = 22). Compared with medium dose, chlorpromazine low dose results in less risk of short-term dystonia (n = 70, 2 RCTs, RR = 0.20, 95% CI = 0.04 to 0.97) and disturbance in general state at medium term (n = 54, 1 RCT, RR = 0.22, 95% CI = 0.08 to 0.60). When low dose is compared with high, the latter shows more clinically important improvement (n = 416, 1 RCT, RR = 1.12, 95% CI = 1.01 to 1.23) but increased dystonia (n = 416, 1 RCT, RR = 0.11, 95% CI = 0.02 to 0.45) and extrapyramidal adverse effects (n = 416, 1 RCT, RR = 0.43, 95% CI = 0.32 to 0.59) (Figure 1). The low-dose group had less risk of a range of a range of adverse effects including in the cardiovascular system (n = 416, 1 RCT, RR = 0.32, 95% CI = 0.19 to 0.54) and central nervous system (n = 416, 1 RCT, RR = 0.17, 95% CI = 0.04 to 0.74). Also dermatologic problems (n = 416, 1 RCT, RR = 0.10, 95% CI = 0.04 to 0.22), the gastrointestinal system (n = 416, 1 RCT, RR = 0.36, 95% CI = 0.21 to 0.62) and for ocular problems (n = 416, 1 RCT, RR = 0.33, 95% CI = 0.22 to 0.50) were less common in this group. There were no comparisons of medium dose versus high. Full details are reported elsewhere.1

Authors’ Conclusions

The average dose of chlorpromazine given to people with schizophrenia has declined across time, but this has come about by long—and sometimes hard—experience rather than from direction from high-grade trial evidence. This progression toward gentler levels of dosing has taken 6 decades. We can hope that for modern compounds dose-ranging studies are more informative early on in the use of a new drug.

Fig. 1.
Chlorpromazine Low Vs High Dose: Extrapyramidal Adverse Effects—Medium Term.

References

1. Liu X, De Haan S. Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst Rev. 2009 in press. [PubMed]

Articles from Schizophrenia Bulletin are provided here courtesy of Oxford University Press